{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:04Z","timestamp":1793383744268,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020154","name":"Protagonist Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.leukres.2025.108132","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:49:21Z","timestamp":1761724161000},"page":"108132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera"],"prefix":"10.1016","volume":"159","author":[{"given":"Lee Ping","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Z.","family":"Ginzburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Kirubamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-2050","authenticated-orcid":false,"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishit B.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Valone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0161-5775","authenticated-orcid":false,"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-9940","authenticated-orcid":false,"given":"Suneel","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2025.108132_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2025.108132_bib2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.108132_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-018-0529-x","article-title":"Polycythemia vera","volume":"19","author":"Spivak","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108132_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.108132_bib7","series-title":"\u00ae (ruxolitinib) tablets, for oral use [prescribing information]","author":"JAKAFI","year":"2023"},{"key":"10.1016\/j.leukres.2025.108132_bib8","series-title":"(ropeginterferon alfa-2b-njft) injection, for subcutaneous use [prescribing information]","author":"BESREMi","year":"2024"},{"issue":"2","key":"10.1016\/j.leukres.2025.108132_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.leukres.2025.108132_bib10","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.108132_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.leukres.2025.108132_bib12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clml.2018.08.009","article-title":"Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States","volume":"18","author":"Grunwald","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.leukres.2025.108132_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2019.09.601","article-title":"Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: an analysis from the REVEAL study","volume":"20","author":"Grunwald","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.108132_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","article-title":"Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review","volume":"5","author":"Parasuraman","year":"2016","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108132_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients in the USA","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.leukres.2025.108132_bib17","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.3390\/jcm13164952","article-title":"Impact of phlebotomy on quality of life in low-risk polycythemia vera","volume":"13","author":"Visweshwar","year":"2024","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.leukres.2025.108132_bib18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00277-022-04826-7","article-title":"Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions","volume":"101","author":"Goulart","year":"2022","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.108132_bib19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.hoc.2010.08.003","article-title":"Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in \u03b2-thalassemia","volume":"24","author":"Gardenghi","year":"2010","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"3","key":"10.1016\/j.leukres.2025.108132_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/ehm.11.22","article-title":"Prospects for a hepcidin mimic to treat \u03b2-thalassemia and hemochromatosis","volume":"4","author":"Parrow","year":"2011","journal-title":"Expert Rev. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2025.108132_bib21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2025.108132_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa2308809","article-title":"Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera","volume":"390","author":"Kremyanskaya","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2023-178253","article-title":"Durability of hematocrit control in polycythemia vera with the first-in-class hepcidin mimetic rusfertide: two-year follow up results from the REVIVE study [abstract]","volume":"142","author":"Ritchie","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2025.108132_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-020-04287-w","article-title":"Is there a gender effect in polycythemia vera?","volume":"100","author":"Palandri","year":"2021","journal-title":"Ann. Hematol."},{"issue":"20","key":"10.1016\/j.leukres.2025.108132_bib26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2025.108132_bib27","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/carcin\/17.11.2455","article-title":"Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice","volume":"17","author":"Yamamoto","year":"1996","journal-title":"Carcinogenesis"},{"issue":"18","key":"10.1016\/j.leukres.2025.108132_bib28","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2025.108132_bib29","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00277-022-04963-z","article-title":"Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera","volume":"101","author":"Triguero","year":"2022","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108132_bib30","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol."},{"issue":"19","key":"10.1016\/j.leukres.2025.108132_bib31","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/03007995.2024.2438996","article-title":"Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices","volume":"41","author":"Lyons","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.leukres.2025.108132_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clml.2024.04.003","article-title":"Contemporary challenges in polycythemia vera management from the perspective of patients and physicians","volume":"24","author":"Kuykendall","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.leukres.2025.108132_bib34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clml.2018.05.020","article-title":"Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States","volume":"18","author":"Mesa","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.leukres.2025.108132_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2025.108132_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","article-title":"Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy","volume":"56","author":"Verstovsek","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2025.108132_bib37","doi-asserted-by":"crossref","unstructured":"Gerds A.T., Kuykendall A.T., Kremyanskaya M., Ritchie E.K., Gotlib J., Palmer J., et al. Final results from the phase 2 REVIVE study investigating the hepcidin mimetic rusfertide in patients with polycythemia vera (PV) [poster]. American Society of Hematology Annual Meeting, December 7-10, 2024, San Diego, CA, Poster 4559.","DOI":"10.1182\/blood-2024-197985"},{"issue":"1","key":"10.1016\/j.leukres.2025.108132_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2023.2299391","article-title":"A safety evaluation of ruxolitinib for the treatment of polycythemia vera","volume":"23","author":"Boldrini","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.leukres.2025.108132_bib39","unstructured":"Malaysian Ministry of Health. Ministry of Health Medicines Formulary 2015 [Available from: \u3008https:\/\/pharmacy.moh.gov.my\/sites\/default\/files\/document-upload\/pfukkm-2-2015-jun.pdf\u3009]."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:10:57Z","timestamp":1773929457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S0145212625006228"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108132","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108132"}}